News

CyPep-1 Shows Preliminary Safety, Tolerability and Early Signs of Efficacy in Part 1 of its Ph I/IIa CICILIA Trial Which Now Moves to Expansion Phase

25/09/2021

Part 1 of the monotherapy trial successfully concluded having reached the planned target dose Favorable safety profile maintained with tolerability…

Cytovation Announces Clinical Collaboration with MSD to Evaluate its First-in-class Tumorolytic Agent CyPep-1 in Combination with KEYTRUDA

30/06/2021

BERGEN, Norway, July 30, 2021 /PRNewswire/ — Cytovation AS, a clinical stage immune-oncology company focused on the development of its first-in-class tumorolytic agent…

Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers

29/05/2020

Bergen, May 29th 2020 – CyPep-1 is a novel lytic immunotherapy that both selectively binds and destroys tumor cells and…

Cytovation and SMS-oncology sign agreement on conduct of phase I/II trial with CyPep-1 in solid tumors

08/08/2019

Bergen, Norway and Schiphol, the Netherlands (8 August 2019) – Cytovation AS (“Cytovation”) and Specialized Medical Services-oncology BV (“SMS-oncology”) today…

Cytovation initiates clinical development programme with CyPep-1,a first-in-class lytic agent for tumor immunotherapy

18/03/2019

BERGEN, NORWAY, 18 March 2019 – Cytovation AS, a privately held biotech company, announces that the first patients have been…

Cytovation announces appointment of Ole-Erik Iversen as Scientific Advisor

20/01/2017

BERGEN, NORWAY, 20 January 2017 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin…

Cytovation announces two key appointments to the management team

03/10/2016

BERGEN, NORWAY, 3rd October 2016 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin disease, announces the…